Revenue and Income - Revenues for the three and six months ended June 30, 2021 were $0, with no active collaboration or licensing agreements, indicating no foreseeable revenue[120][121] - Total income tax benefit for the three months ended June 30, 2021 was $964, a 237% increase from $286 in the same period of 2020[136] - The company expects to incur substantial operating losses in the future and cannot guarantee significant product revenues until FDA or EMA approval[146] Research and Development Expenses - Total research and development expenses for the three months ended June 30, 2021 were $4.1 million, a 253% increase from $1.16 million in the same period of 2020[123] - Research and development expenses for the six months ended June 30, 2021 totaled $6.67 million, a 194% increase from $2.27 million in the same period of 2020[125] - The company anticipates an increase in overall research and development expenses for the year ended December 31, 2021 compared to 2020 as clinical development programs progress[127] General and Administrative Expenses - General and administrative expenses for the three months ended June 30, 2021 were $1.999 million, a 53% increase from $1.309 million in the same period of 2020[128] - General and administrative expenditures for the year ended December 31, 2021 are expected to increase by approximately 12% compared to 2020 due to lease assignation premium and increased legal and recruitment costs[130] Cash and Working Capital - Cash and cash equivalents as of June 30, 2021 were $43.639 million, up from $25.342 million as of June 30, 2020[139] - Total working capital as of June 30, 2021 was $43.085 million, compared to $26.421 million as of June 30, 2020[139] - Existing funds and cash generated from operations are expected to satisfy planned working capital and capital expenditures through early 2023, but not sufficient for drug candidate development[147] Cash Flow Activities - Net cash used in operating activities increased by $3.1 million, from $4.7 million in 2020 to $7.8 million in 2021[141] - Net cash used in investing activities increased by $12,000 primarily due to increased capital expenditures on IT[142] - Net cash provided by financing activities was $17.9 million in 2021, resulting from approximately $13.5 million in net proceeds from common stock issuance and $4.5 million from warrant exercises[143] Future Funding and Financial Strategy - Future funding requirements will depend on clinical trial costs, manufacturing capabilities, and the impact of COVID-19 on operations[148] - The company plans to finance future cash needs primarily through equity offerings, debt financings, or strategic collaborations[150] - The company is evaluating in-licensing and acquisition opportunities to access new drugs or drug targets, which may increase future funding needs[147] Accumulated Deficit - The accumulated deficit as of June 30, 2021 was $374.7 million, indicating significant losses since inception[139]

Financial Performance - The company reported no revenues for the three months ended March 31, 2020 and 2021, indicating a lack of active collaboration or licensing agreements[114][115]. - The accumulated deficit as of March 31, 2021, was $369.6 million, reflecting significant losses since inception[133]. - The company expects to incur substantial operating losses in the future and cannot guarantee significant product revenues until FDA or EMA approval and successful commercialization[139]. Research and Development Expenses - Research and development expenses increased by $1.5 million from $1.1 million in Q1 2020 to $2.6 million in Q1 2021, representing a 132% increase[120]. - Research and development expenses for transcriptional regulation (fadraciclib) increased by $0.8 million from $0.9 million in Q1 2020 to $1.7 million in Q1 2021, an 88% increase[120]. Cash Flow and Working Capital - Cash and cash equivalents increased significantly from $8.9 million in March 2020 to $47.8 million in March 2021[133]. - Total working capital improved from $10.3 million in March 2020 to $47.7 million in March 2021[133]. - Net cash used in operating activities increased by $0.8 million, from $2.8 million in Q1 2020 to $3.6 million in Q1 2021[135]. - Net cash provided by financing activities surged from a net outflow of $50,000 in Q1 2020 to a net inflow of $18.0 million in Q1 2021[134]. - Net cash provided by financing activities increased by approximately $18.0 million for the three months ended March 31, 2021, due to $13.5 million from common stock issuance and $4.5 million from warrant exercises[137]. Future Funding and Financial Strategy - Existing funds and cash generated from operations are expected to satisfy planned working capital and capital expenditures through early 2023, but the company lacks sufficient funds for drug candidate development and commercialization[140]. - Future funding requirements will depend on clinical trial costs, manufacturing capabilities, and the impact of COVID-19 on financial conditions and operations[141]. - The company plans to finance future cash needs primarily through public or private equity offerings, debt financings, or strategic collaborations[142]. - The company is not reliant on institutional credit finance, but it is dependent on the availability of funds and equity market activity[142]. Impact of COVID-19 - The impact of the COVID-19 pandemic on the company's financial condition and operations remains uncertain and could materially affect future capital raising and clinical studies[144].

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2021 Earnings Conference Call May 12, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and CMO Conference Call Participants Jonathan Aschoff - ROTH Capital Kevin DeGeeter - Oppenheimer Wangzhi Li - Ladenburg Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2021 Results Conference Call and Webcast. At this time, all participants are in a liste ...

Translating cancer biology into medicines March 15, 2021 33rd Annual Roth Conference Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. ("Cyclacel"). By their nature, forward-looking statements and forecasts involve risks and uncertainties ...

Translating cancer biology into medicines February 2021 Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- looking statements and forecasts involve risks and uncertainties because they relate to events and depend o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 00-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91-1707622 (State or Other Jurisdiction of Incorp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as sp ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Eric Ando – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum – Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff – Roth Capital Partners Kumar Raja – Brookline Capital Wangzhi Li – Ladenburg Operator Good afternoon, and w ...

Translating cancer biology into medicines October 2020 Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- looking statements and forecasts involve risks and uncertainties because they relate to events and depend on ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specifi ...